ArticleCureus2024
Correlation Between Transient Elastography and Non-invasive Biomarker Scores for the Detection of Liver Fibrosis.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Serum Gremlin 1 Remains Elevated Following Successful Direct-Acting Antiviral Therapy for Chronic Hepatitis C.Viruses · 2026Article
- Dual-phase T1-mapping (DHR-MAP) for non-invasive assessment of advanced liver fibrosis and moderate hepatitis: a single-center validation study.BMC gastroenterology · 2026Article
- Review
- Diagnostic Performance of Fibrosis-4 Index, Nonalcoholic Fatty Liver Disease Fibrosis Score, AST-To-Platelet Ratio Index, and BARD Score Among Young and Older Adults for the Diagnosis of Advanced MASLD Fibrosis: A Retrospective Cohort Study.JGH open : an open access journal of gastroenterology and hepatology · 2025Article
- FIB-4 Score as a Predictor of Eligibility for Elastography Exam in Patients with Polycystic Ovary Syndrome.Biomedicines · 2025Article
- [Research progress on the impact of metabolic associated fatty liver disease on viral activity, treatment response, and prognosis in patients with chronic hepatitis B: current status and prospects].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and aim The study aimed to address the need for reliable and non-invasive biomarkers (NIBM) for detecting fibrosis among patients with chronic liver disease (CLD). Material and methods This was a diagnostic validation study executed at the Department of Gastroenterology, Jinnah Hospital, Lahore. The study was carried out from July 2023 to June 2024, enrolling a total of 88 patients using non-probability consecutive sampling. Patients with chronic liver disease (CLD) due to chronic viral hepatitis B (HBV), hepatitis C (HCV), and non-alcoholic fatty liver disease (NAFLD) were included in the study. A cut-off value of 12.5 kPa was used to label fibrosis using transient elastography. Blood samples were collected for recording values of alanine aminotransferase (ALT), aspartate aminotransferase (AST), and platelet count, and the appropriate formulas were applied to calculate the aspartate aminotransferase to platelet ratio index (APRI), Fibrosis-4 (FIB-4), AST/ALT-to-platelet ratio index (AARPRI), and BARD scores (a scoring system for NAFLD fibrosis that predicts the risk of advanced fibrosis in NAFLD patients; the components include body mass index (BMI), aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ratio, and diabetes status). Spearman's rank correlation coefficient was used to assess the strength and direction of the association between these variables. Results Among the 88 patients, 61.4% were male and HCV was the most common cause of CLD (63.6%). Statistically significant correlations were found between transient elastography and NIBM: FIB-4 (p < 0.001, area under receiver operating characteristic curves (AUROC), 0.835; sensitivity, 47.7%; specificity, 90.9%), APRI (p = 0.020; AUROC, 0.769; sensitivity, 25.0%; specificity, 93.2%), AARPRI (p = 0.011, AUROC, 0.782), and BARD (p = 0.033; AUROC, 0.648). FIB-4 demonstrated the strongest correlation with liver stiffness measurements (LSM) (r = 0.617), indicating its reliability in detecting liver fibrosis, whereas the aspartate aminotransferase to alanine aminotransferase ratio (AAR) showed the weakest correlation (r = 0.163). Conclusion This study reported that FIB-4 displayed the highest correlation with liver stiffness measurements obtained through transient elastography in detecting liver fibrosis. APRI and AARPRI reported a moderate correlation, while AAR and BARD were less consistent in their performance. These findings suggest that FIB-4, APRI, and AARPRI are effective non-invasive tools for assessing liver fibrosis in a limited resource setting where transient elastography is not available.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.